Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas
Roberto Piva(University of Turin), Giorgio Inghirami(Cornell University)
Cited by 128
Related Papers
Differential Reactivity of a Novel Monoclonal Antibody (DF3) with Human Malignant versus Benign Breast Tumors
|Hybridoma|1984|580
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
|Cancer Cell|2016|304
NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors
|Blood|2003|247
Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and Bcl2A1 as critical target genes
|Journal of Clinical Investigation|2006|164